What is a new drug worth? An innovative model for performance-based pricing-Reference-Cited by-同舟云学术

What is a new drug worth? An innovative model for performance-based pricing

Published:2014-09-25 Issue:3 Volume:24 Page:313-320
ISSN:0961-5423
Container-title:European Journal of Cancer Care
language:en
Short-container-title:Eur J Cancer Care (Engl)

Author:

Dranitsaris G.¹,Dorward K.²,Owens R.C.²,Schipper H.²

Affiliation:

1. School of Medicine; University of Ioannina; Ioannina Greece

2. University of Toronto; Toronto Ontario Canada

Publisher

Wiley

Subject

Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ecc.12240/fullpdf

Reference27 articles.

1. Anand G. 2007 From Wall Street, a Warning About Cancer-Drug Prices http://online.wsj.com/news/articles/SB117391934158537592

2. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts;Anonymous;Blood,2013

3. Are QALYs an appropriate measure for valuing morbidity in acute diseases?;Bala;Health Economics,2000

4. Cancer Research UK 2012 NICE's end of life criteria http://www.cancerresearchuk.org/about-us/we-develop-policy/our-policy-on-access-to-cancer-treatments/our-policy-on-cancer-drugs

5. Charlish P. 2010 Problems with risk-sharing study must not deter future collaborations http://www.rajpharma.com/productsector/pharmaceuticals/Problems-with-UK-risk-sharing-study-must-not-deter-future-collaborations-297233

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis;International Journal of Environmental Research and Public Health;2020-11-10

2. Medicines and economic constraints;British Journal of Healthcare Management;2020-08-02

3. Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs;Expert Review of Pharmacoeconomics & Outcomes Research;2018-04-25

4. Funding breakthrough therapies: A systematic review and recommendation;Health Policy;2018-03

5. An assessment of innovative pricing schemes for the communication of value: is price discrimination and two-part pricing a way forward?;Expert Review of Pharmacoeconomics & Outcomes Research;2017-12-04